Anemia of Chronic Disease: Next Step When IV Iron Therapy Has Not Corrected Iron Deficiency
When IV iron therapy fails to achieve successful correction of iron deficiency in a patient with anemia of chronic disease (AI), a structured next-line approach is indicated. No response to iron therapy supports the diagnosis of AI and points toward a different class of intervention.
Prior Line — IV Iron Therapy Did Not Reach Its Goal
The previous treatment step involved IV iron therapy — including older formulations such as ferric gluconate or ferric sucrose, as well as newer glycan-coated nanoparticle formulations such as iron carboxymaltose, iron isomaltoside, and ferumoxytol. The target of that line was successful correction of iron deficiency. When that goal is not reached, escalation is indicated.
Next-Line Treatment Approach
The next-line regimen for AI involves erythropoiesis-stimulating agent (ESA) therapy. Recombinant human ESAs have been used for the treatment of AI in this setting — the complete combination, sequencing, and clinical considerations are contained in the full protocol.
Treatment Goal
The clinical objective at this stage is improvement of anemia with an increase in hemoglobin.
References
DOI: 10.1016/j.kint.2025.06.006
- No response to iron therapy would support the diagnosis of AI, suggesting that ESA therapy may be beneficial.
- Recombinant human ESAs have been used successfully for the treatment of AI for many years, specifically in patients with cancer or renal failure or when iron supplementation alone was ineffective.
- In addition to treatment of the disease underlying AI, the combination of iron therapy and erythropoiesis-stimulating agents can improve anemia in many patients.